85 related articles for article (PubMed ID: 1361349)
1. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
Slade H; Turner J; Abrams C; Carlo D; Salk J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
[No Abstract] [Full Text] [Related]
2. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial.
Turner JL; Trauger RJ; Daigle AE; Carlo DJ
AIDS; 1994 Oct; 8(10):1429-35. PubMed ID: 7818813
[TBL] [Abstract][Full Text] [Related]
4. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
[TBL] [Abstract][Full Text] [Related]
6. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
[TBL] [Abstract][Full Text] [Related]
7. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
[TBL] [Abstract][Full Text] [Related]
8. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
[TBL] [Abstract][Full Text] [Related]
9. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
10. Inactivated HIV-1 Immunogen: impact on markers of disease progression.
Moss RB; Ferré F; Trauger R; Jensen F; Daigle A; Richieri SP; Carlo DJ
J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S21-7. PubMed ID: 7910207
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
[TBL] [Abstract][Full Text] [Related]
12. Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection.
Wallace MR; Moss RB; Beecham HJ; Grace CJ; Hersh EM; Peterson E; Murphy R; Shepp DH; Siegal FP; Turner JL; Safrin S; Carlo DJ; Levine AM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):358-62. PubMed ID: 8673544
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
[TBL] [Abstract][Full Text] [Related]
14. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
[TBL] [Abstract][Full Text] [Related]
15. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.
Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
APMIS; 2012 Mar; 120(3):204-9. PubMed ID: 22339677
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
[No Abstract] [Full Text] [Related]
17. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.
Franco D; Li W; Qing F; Stoyanov CT; Moran T; Rice CM; Ho DD
Vaccine; 2010 Aug; 28(35):5676-85. PubMed ID: 20600494
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]